Kaplan–Meier analysis showed that ESCC patients with FGFR1 amplification had significantly shorter OS (32.0 months; range, 11.0 to 116.0 months) than those without FGFR1 amplification (50.0 months; range, 9.0 to 137.0 months) (log rank; P<0.001) (Figure 2). This evidence concerns the gene FGFR1 and esophageal squamous cell carcinoma.